Navigation Links
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Date:10/17/2007

BOULDER, Colo., Oct. 17 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today announced the initiation of an international pivotal Phase 3 clinical trial evaluating amrubicin, the Company's third-generation synthetic anthracycline, in the treatment of second-line small cell lung cancer (SCLC). The randomized, controlled, multi-center study will compare amrubicin to topotecan, the only approved chemotherapy for second-line treatment of SCLC in the US and EU. Enrollment in the study of 480 patients is underway.

Approximately 30,000 patients in the US and 32,000 patients in the EU will be diagnosed with SCLC this year. "The treatment of small cell lung cancer is extremely challenging, given the limited therapeutic options available," said Mark A. Socinski, Associate Professor of Medicine, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, and a principal investigator in the Phase 3 study. "Preliminary data suggest that amrubicin could represent a significant improvement in the treatment of small cell lung cancer, for which there have been no major medical advances in more than 20 years."

The study compares amrubicin and topotecan in second-line treatment of SCLC patients with sensitive or refractory disease. Sensitive disease is defined as response to first-line platinum-based therapy, with subsequent progression 90 days or more after completion of therapy. Refractory disease is defined as no objective response or progressive disease within 90 days of completion of therapy. Study participants are randomized in a 2:1 ratio to receive either IV amrubicin (40mg/m2 daily for 3 days) or topotecan (1.5 mg/m2 daily for 5 days), both starti
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
7. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
10. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
11. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  MGC Diagnostics Corporation ... global medical technology company, today scheduled a conference call ... of fiscal year 2013, ended April 30, 2013. The ... May 30, 2013. The Company will report financial results ... the markets close on Thursday, May 30, 2013. ...
(Date:5/23/2013)... KNOXVILLE, Tenn. , May 23, 2013 /PRNewswire/ ... of 24-hour nurse triage and nurse advice lines, ... 10-person committee, comprising physician, nursing and administrative leaders, ... providing safe, quality and cost-effective services for hospital ... "As our national healthcare system evolves, it,s imperative ...
(Date:5/23/2013)... IRVINE, Calif. , May 23, 2013 ... breast cancer may not benefit from chemotherapy and still ... announced the launch of one of the largest sources ... The new website and interactive Facebook page provide recently ... if they can safely avoid chemotherapy. "We ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3
... Sept. 7 Epeius Biotechnologies Corporation, a leader in ... publication of a landmark paper in clinical oncology. Following ... of Rexin-G in chemo-resistant metastatic pancreatic cancer ( Molecular ... Drug and FDA Fast Track Status, this new paper ...
... India, Sept. 7 Sun Pharmaceutical Industries Ltd. (Sun) ... today announced that the Supreme Court of Israel has ... (Taro) (Pink Sheets: TAROF ) of the ... the Israeli special tender offer (STO) rules do not ...
Cached Medicine Technology:To Reach, Perchance to Kill the Cancer: A Soliloquy From Epeius Nanotechnologies Opposes That 'Sea of Troubles' 2Supreme Court of Israel Rules in Favor of Sun Pharma 2Supreme Court of Israel Rules in Favor of Sun Pharma 3
(Date:5/25/2013)... Studies from Johns Hopkins University reveal ... weight and their inability to get adequate sleep. These ... can naturally relieve many symptoms. , Johns Hopkins ... quality was significantly associated with overall weight loss, especially ... dated November 6th, 2012, researchers monitored 77 participants who ...
(Date:5/25/2013)... York (PRWEB) May 25, 2013 Pradaxa ... suffered serious, life-threatening episodes of internal bleeding while using the ... in U.S. District Court, Southern District of Illinois, Bernstein Liebhard ... website, 818 Pradaxa side effect claims had been ... That’s up from 705 claims reported by the Court on ...
(Date:5/25/2013)... According to a new market report,"Global Homeland ... MarketsandMarkets is expected to reach $544.02 Billion by ... and studies the major market drivers, restraints, and ... of the World. , Browse:, , ... 87 Figures , 175 Pages and ...
(Date:5/25/2013)... Acuity Games ’ innovative brain games have come ... Hunt is available today, expanding it beyond its iPad ... Sudoku and Matchematics will roll out over the next 30 ... brain fitness measurement have been re-optimized for the iPhone's 3.5 ... fitness measurement in your pocket. What could be better?” ...
(Date:5/25/2013)... 2013 For college students, few ... Increasingly, they are turning to prescription stimulants like ... For more on this, go to http://www.sciencedaily.com/releases/2013/05/130501145151.htm ... warns that students who pick up Adderall, “just ... for developing a physical and psychological dependency. While ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4Health News:Acuity Games Apps Come to the iPhone 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2
... Steven Reinberg HealthDay Reporter , THURSDAY, March 10 (HealthDay ... -- or even five cups -- daily may be reducing their ... research shows. And women who don,t drink coffee at all ... researchers noted. However, the researchers added, these findings are preliminary ...
... will find Major League pitchers practicing their pitches, perfecting ... grueling 162 game season. A new study published in ... for Psychological Science, suggests that hurlers might also consider ... brains. The study, led by researchers from Duke ...
... Man,s best friend may provide more than just faithful companionship: ... shows people who owned and walked their dogs were 34 ... The results, said epidemiologist Mathew Reeves, show that promoting ... of which fewer than half meet recommended levels of leisure-time ...
... HealthDay Reporter , THURSDAY, March 10 (HealthDay News) -- ... advantage these days often turn to what,s been nicknamed ... young minds. But researchers and pediatricians have begun ... these videos. And new studies are finding that the ...
... March 10, 2011 In an effort to improve ... cancer, the TGen Foundation today joined with key donors ... The backbone of globalCure is an alliance between ... includes leading pancreatic cancer scientists, physicians and researchers, armed ...
... -- You may have a higher long-term risk of disease ... in rats suggests. U.K. researchers found that rats were ... were malnourished while they were pregnant. The study was published ... Academy of Sciences . , , In the study, a ...
Cached Medicine News:Health News:Can Coffee Cut a Woman's Stroke Risk? 2Health News:Can Coffee Cut a Woman's Stroke Risk? 3Health News:Pitchers bean more batters in the heat of the summer 2Health News:Grab the leash: Dog walkers more likely to reach exercise benchmarks 2Health News:Popular Baby Media May Not Actually Advance Learning 2Health News:Popular Baby Media May Not Actually Advance Learning 3Health News:TGen Foundation launches 'globalCure,' targets pancreatic cancer 2Health News:Poor Diet in Pregnancy Tied to Disease in Offspring: Rat Study 2
... monitoring for flexible care settings., ... combine portability and measurement flexibility to ... of intermediate care environmentsat the patients ... heritage in patient monitoring, IntelliVue has ...
... hospital-grade monitoring capabilities into the growing health ... state management. The system is unique ... range of clinical applications, from continuous real-time ... periodic monitoring of patients outside the hospital, ...
Generra Focus 5 is a basic vital sign monitor. , ,Adult, pediatric, and neonatal. , ,Providing high quality, affordable products for efficiency in patient care....
... The Acuity Central Monitoring Station ... for up to 60 patients from ... interface uses simple point and click ... trackball. The clinician can initiate or ...
Medicine Products: